Last reviewed · How we verify
PRG-1801 (CAR-T against BCMA) — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
PRG-1801 (CAR-T against BCMA) (PRG-1801 (CAR-T against BCMA)) — Lingli Dong.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PRG-1801 (CAR-T against BCMA) TARGET | PRG-1801 (CAR-T against BCMA) | Lingli Dong | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PRG-1801 (CAR-T against BCMA) CI watch — RSS
- PRG-1801 (CAR-T against BCMA) CI watch — Atom
- PRG-1801 (CAR-T against BCMA) CI watch — JSON
- PRG-1801 (CAR-T against BCMA) alone — RSS
Cite this brief
Drug Landscape (2026). PRG-1801 (CAR-T against BCMA) — Competitive Intelligence Brief. https://druglandscape.com/ci/prg-1801-car-t-against-bcma. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab